tbuckley/cabot-search huggingface dataset:
Chromosomal Instability in Cell-Free DNA as a Highly Specific Biomarker for Detection of Ovarian Cancer in Women with Adnexal Masses
Authors: Adriaan Vanderstichele, Pieter Busschaert, Dominiek Smeets, Chiara Landolfo, Els Van Nieuwenhuysen, Karin Leunen, Patrick Neven, Frédéric Amant, Sven Mahner, Elena Ioana Braicu, Robert Zeilinger, An Coosemans, Dirk Timmerman, Diether Lambrechts, Ignace Vergote
Journal: Clinical Cancer Research (2016)

Purpose: Chromosomal instability is a hallmark of ovarian cancer. Here, we explore copy-number alteration (CNA) profiling in cell-free DNA as a potential biomarker to detect malignancy in patients presenting with an adnexal mass.Experimental Design: We prospectively enrolled 68 patients with an adnexal mass, of which 57 were diagnosed with invasive or borderline carcinoma and 11 with benign disease. Cell-free DNA was extracted from plasma and analyzed by low-coverage whole-genome sequencing.Results: Patterns of chromosomal instability were detectable in cell-free DNA using 44 healthy individuals as a reference. Profiles were representative of those observed in matching tumor tissue and contained CNAs enriched in two large datasets of high-grade serous ovarian cancer (HGSOC). Quantitative measures of chromosomal instability, referred to as genome-wide z-scores, were significantly higher in patients with ovarian carcinoma than in healthy individuals or patients with benign disease. Cell-free DNA testing improved malignancy detection (AUC 0.89) over serum CA-125 (AUC 0.78) or the risk of malignancy index (RMI, AUC 0.81). AUC values of cell-free DNA testing even further increased for HGSOC patients specifically (AUC 0.94). At a specificity of 99.6%, a theoretical threshold required for ovarian cancer screening, sensitivity of cell-free DNA testing was 2- to 5-fold higher compared with CA-125 and RMI testing.Conclusions: This is the first study evaluating the potential of cell-free DNA for the diagnosis of primary ovarian cancer using chromosomal instability as a read-out. We present a promising method to increase specificity of presurgical prediction of malignancy in patients with adnexal masses. Clin Cancer Res; 23(9); 2223-31. ©2016 AACR.
GCSF Alone or in Combination with Cyclophosphamide (C) or GM-CSF for Hematopoietic Stem Cell Mobilization (HSCM) for Autologous Peripheral Blood Stem Cell Transplant (AHPCT): A Retrospective Review of a Single Center Experience
Authors: Sunil Abhyankar, Barry Skikne, Delva Deauna, Dean Merkel, David Bodensteiner, Omar Aljitawi, Sid Ganguly, Joseph Mcguirk
Journal: Blood (2008)
Continuous Positive Airway Pressure Improves Quality of Life in Women with Obstructive Sleep Apnea. A Randomized Controlled Trial
Authors: Francisco Campos-Rodriguez, Carlos Queipo-Corona, Carmen Carmona-Bernal, Bernabe Jurado-Gamez, Jose Cordero-Guevara, Nuria Reyes-Nuñez, Fernanda Troncoso-Acevedo, Araceli Abad-Fernandez, Joaquin Teran-Santos, Julian Caballero-Rodriguez, Mercedes Martin-Romero, Ana Encabo-Motiño, Lirios Sacristan-Bou, Javier Navarro-Esteva, Maria Somoza-Gonzalez, Juan F. Masa, Maria A. Sanchez-Quiroga, Beatriz Jara-Chinarro, Belen Orosa-Bertol, Miguel A. Martinez-Garcia
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

Continuous positive airway pressure (CPAP) is the treatment of choice in patients with symptomatic obstructive sleep apnea (OSA). CPAP treatment improves quality of life (QoL) in men with OSA, but its role in women has not yet been assessed.To investigate the effect of CPAP on QoL in women with moderate to severe OSA.We conducted a multicenter, open-label randomized controlled trial in 307 consecutive women diagnosed with moderate to severe OSA (apnea-hypopnea index, ≥15) in 19 Spanish sleep units. Women were randomized to receive effective CPAP therapy (n = 151) or conservative treatment (n = 156) for 3 months. The primary endpoint was the change in QoL based on the Quebec Sleep Questionnaire. Secondary endpoints included changes in daytime sleepiness, mood state, anxiety, and depression. Data were analyzed on an intention-to-treat basis with adjustment for baseline values and other relevant clinical variables.The women in the study had a mean (SD) age of 57.1 (10.1) years and a mean (SD) Epworth Sleepiness Scale score of 9.8 (4.4), and 77.5% were postmenopausal. Compared with the control group, the CPAP group achieved a significantly greater improvement in all QoL domains of the Quebec Sleep Questionnaire (adjusted treatment effect between 0.53 and 1.33; P < 0.001 for all domains), daytime sleepiness (-2.92; P < 0.001), mood state (-4.24; P = 0.012), anxiety (-0.89; P = 0.014), depression (-0.85; P = 0.016), and the physical component summary of the 12-item Short Form Health Survey (2.78; P = 0.003).In women with moderate or severe OSA, 3 months of CPAP therapy improved QoL, mood state, anxiety and depressive symptoms, and daytime sleepiness compared with conservative treatment. Clinical trial registered with www.clinicaltrials.gov (NCT02047071).
SAT0522 Efficacy and Safety of Ultrasonographic Guided Percutaneous Needle Planter Fasciotomy as A Treatment for Chronic Planter Fasciitis: Table 1.
Authors: M. Mortada, D.M. Sharaf, M.A.H. Hammad, N. Ezzeldin
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Plantar fasciitis (PF) is the most common cause of heel pain. Approximately 10% of the cases develop recalcitrant symptoms and are offered various forms of surgical intervention. Ultrasound guided needle planter fasciotomy is a minimal invasive method that may help this group of patients (1). <h3>Objectives</h3> To assess the efficacy and safety of ultrasonographic guided percutaneous needle planter fasciotomy as a treatment for chronic planter fasciitis. <h3>Methods</h3> ultrasound guided planter fasciotomy (1) was carried out in one hundred and seven patients who had chronic planter fasciitis that did not respond to conservative treatment including medical treatment, physiotherapy and local corticosteroid injection. Following induction of local anesthesia, a 14-gauge needle was guided toward and into the plantar fascia by real-time sonography.Visual analogue scale (VAS) for heel pain and ultrasonographic character of planter fascia (thickness and echogenicity) were assessed on the initial (W0), 2 weeks later (W2) and 6 months after treatment (W24). <h3>Results</h3> A highly significant difference was found between VAS and sonographic findings before and after fasciotomy. Patients improved significantly at 2 weeks compared to baseline and also at 6 months compared to baseline and 2 weeks (table 1). Nighty seven (90.7%) of patients stated that "the procedure had been worthwhile". There were no complications during or following needle fasciotomy. <h3>Conclusions</h3> Ultrasonographic guided percutaneous needle planter fasciotomy is a safe and an effective method in patients with chronic planter fasciitis who did not respond to conservative treatments including local corticosteroid injections. <h3>References</h3> Folman et al, Foot and Ankle Surgery 11 (2005) 211–214 <h3>Disclosure of Interest</h3> None declared
Bortezomib Partially Overcomes TNF-Related Apoptosis Inducing ligand/Apo-2L (TRAIL/Apo-2L) Environment Mediated-Drug Resistance (EM-DR).
Authors: Nancy Parquet, Ramadevi Nimmanapalli, Claudio Anasetti, Melissa Alsina, William Dalton, Lia E. Perez
Journal: Blood (2004)
AB0120 Cytokine Gene Expression MRNA Profile of Peripheral Blood Cells in Ankylosing Spondylitis
Authors: M. Ivanova Goycheva, I. Manolova, L. Miteva, R. Stoilov, S. Stanilova
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Objectives</h3> The aim of the present study was to investigate cytokine gene-expression profile into peripheral blood cells from Bulgarian patients with ankylosing spondylitis (AS). <h3>Methods</h3> Total RNA from peripheral blood was isolated from 12 healthy controls and 20 patients with AS with a mean disease duration of 13.2 years (range 2.9 - 26). Nine of the patients were only on first-line therapy, a non-steroidal anti-inflammatory drug (NSAID) and 11 were being treated with TNF-blocking agents. cDNAs were used for TaqMan gene expression assays of IL10, TGFB1, IL23A, IL12B, TNFA, IL18, Foxp3 and GAPDH. Relative quantitative evaluation of mRNAs was performed by the comparative ΔΔCt method and results are presented as relative quantity (RQ). <h3>Results</h3> From all examined cytokine genes in AS, we found up-regulated most of them in the following order according to RQ values: IL12B&gt;IL23A&gt;TGFB&gt;IL10&gt;IL18. The gene expression of IL23A and IL12B was significantly higher (p=0.016; RQ=2.04; RQ=2.64, respectively) into peripheral blood cells from AS patients compared to controls, whereas TGFB, IL10 and IL18 were slightly but not significant overexpressed (RQ vary from 1.2 to 1.4.) In contrast, a significant down regulation of TNFA (RQ=0.716; p=0.02) was observed among investigated patients compared to controls. In addition, mRNA expression of FoxP3, a transcription factor driving regulatory FoxP3+ T cells was also down regulated in AS patients (RQ=0.455; p=0.0014). In terms of drug usage, the cytokine gene expression profile between AS patients treated with TNF inhibitors and those without TNF-blocking agents was comparable. A positive correlation was found between gene expression of IL23A with TNFA and IL18 in AS (r=0.67, p=0.001; r=0.456, p=0.038, respectively) and negative correlation between IL23A and TGFB1 (r=-0.58, p=0.006). <h3>Conclusions</h3> Our results demonstrated differences in the expression of mRNA encoded regulatory and effector cytokines in peripheral blood cells of AS patients pointed on IL-23 and cytokine related transcription factor FoxP3. <h3>Disclosure of Interest</h3> None declared
Non-Standard Doses of Dasatinib Sustain Cytogenetic Response In Chronic Myeloid Leukemia (CML) Patients
Authors: Fernanda Salles Seguro, Mariana Gomes Serpa, Marcela Cavalcante de Andrade Silva, Daniel Salas Steinbaum, Thales DM Pereira, Flavia Dias Xavier, Claudia Bitti Barroso, Israel Bendit, Pedro E Dorlhiac Llacer
Journal: Blood (2010)
Parallel Transcriptional Analysis of Multiple Stem and Progenitor Populations Identifies Novel Commonly Dysregulated and Functionally Relevant Targets in AML
Authors: Laura Barreyro, Britta Will, Boris Bartholdy, Li Zhou, Tihomira I Todorova, Robert Stanley, Susana Ben-Neriah, Cristina Montagna, Samir Parekh, Andrea Pellagatti, Jacqueline Boultwood, Elisabeth Paietta, Rhett P Ketterling, Larry D Cripe, Hugo F Fernandez, Peter L. Greenberg, Jacob M Rowe, Martin S. Tallman, Christian Steidl, Constantine S. Mitsiades, Amit Verma, Ulrich Steidl
Journal: Blood (2012)
Changes in the Delivery of Standard Chemotherapeutic Agents during Induction Affect Early Measures of Minimal Residual Disease (MRD): POG 9900 for Patients with B-Precursor Low and Standard Risk ALL.
Authors: Naomi Winick, Michael J. Borowitz, Mini Devidas, Paul L. Martin, Jeanette Pullen, Stephen P. Hunger, William L. Carroll, Bruce Camitta
Journal: Blood (2006)
Stem Cell Transplant (SCT) and Pralatrexate Therapy: Outcome of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma Who Received SCT Prior to or Following Pralatrexate Therapy.
Authors: Leslie Popplewell, Barbara Pro, Eric Jacobsen, Steven M. Horwitz, Adam Boyd, Molly Patterson, Steven Fruchtman, Owen A O'Connor
Journal: Blood (2009)
Outcomes Following Allogeneic Hematopoietic Cell Transplantation (HCT) Using Non-Myeloablative Conditioning with Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) Confirm a Low Incidence of Graft Versus Host Disease (GVHD) with Retained Anti-Tumor Activity
Authors: Holbrook Kohrt, Brit Turnbull, G. Laport, D. Miklos, J. Shizuru, L. Johnston, S. Arai, W. K. Weng, J. Benjamin, K. Blume, R. Negrin, P. Lavori, S. Strober, R. Lowsky
Journal: Blood (2008)
Association of Cardiovascular Risk Factors and Stroke With Alzheimer Disease—Reply
Authors: Giuseppe Tosto, Richard Mayeux
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Relapse of Acute Myeloid Leukemia after Allogeneic Stem-Cell Transplantation (SCT) with Myeloablative Conditioning Is Associated with Longer Survival Than Relapse after Reduced-Intensity Conditioning (RIC).
Authors: Avichai Shimoni, Izhar Hardan, Noga Shem-Tov, Avital Rand, Elena Ribakovsky, Ronit Yerushalmi, Arnon Nagler
Journal: Blood (2007)
Clinical Features Associated With Individuals at Higher Risk of Melanoma
Authors: Caroline G. Watts, Christine Madronio, Rachael L. Morton, Chris Goumas, Bruce K. Armstrong, Austin Curtin, Scott W. Menzies, Graham J. Mann, John F. Thompson, Anne E. Cust
Journal: JAMA Dermatology (2016)

The identification of a subgroup at higher risk of melanoma may assist in early diagnosis.To characterize melanoma patients and the clinical features associated with their melanomas according to patient risk factors: many nevi, history of previous melanoma, and family history of melanoma, to assist with improving the identification and treatment of a higher-risk subgroup.The Melanoma Patterns of Care study was a population-based observational study of physicians' reported treatment of 2727 patients diagnosed with an in situ or invasive primary melanoma over a 12-month period from October 2006 to 2007 conducted in New South Wales. Our analysis of these data took place from 2015 to 2016.Age at diagnosis and body site of melanoma.Of the 2727 patients with melanoma included, 1052 (39%) were defined as higher risk owing to a family history of melanoma, multiple primary melanomas, or many nevi. Compared with patients with melanoma who were at lower risk (ie, without any of these risk factors), the higher-risk group had a younger mean age at diagnosis (62 vs 65 years, P < .001), but this differed by risk factor (56 years for patients with a family history, 59 years for those with many nevi, and 69 years for those with a previous melanoma). These age differences were consistent across all body sites. Among higher-risk patients, those with many nevi were more likely to have melanoma on the trunk (41% vs 29%, P < .001), those with a family history of melanoma were more likely to have melanomas on the limbs (57% vs 42%, P < .001), and those with a personal history were more likely to have melanoma on the head and neck (21% vs 15%, P = .003).These findings suggest that a person's risk factor status could be used to tailor surveillance programs and education about skin self-examination.
Immune Ablation Using Cyclophosphamide without Stem Cell Rescue for Intractable Multiple Sclerosis and Its Variants
Authors: Julie R Nangia, Jamile M. Shammo, Shilpa D Tilwalli, Roumen Balabanov, Dusan Stefoski, George Katsamakis, Michael Ko, Neel B Shah, Mohamed I Farhat, Alla Gimelfarb, Kathryn Shell, Katherine Bueschel, Stephanie A. Gregory
Journal: Blood (2008)
Comparative genome-wide analyses of gene expression and genetic alteration in neuroblastomas detected by mass screening and clinical symptoms.
Authors: Eiso Hiyama, Keiko Hiyama, Hiroaki Yamaoka, Masahiko Nishiyama, Charles Patrick Reynolds, Taijiro Sueda
Journal: Cancer Research (2006)

5633   Introduction: Biological heterogeneity of neuroblastoma, a malignant childhood tumor, results in favorable or unfavorable outcomes. In Japan, mass-screening program for detecting neuroblastoma in 6-month-old infants had been performed for approximately 20 years and more than 98 % of the patients with mass-screening (MS) detected tumors showed favorable prognosis. To gain new insights into the biology of this tumor, especially into spontaneous regression or maturation mechanisms in this tumor, we performed microarray analysis and compared the gene expression profiles and gene alterations of NB including the mass screening detecting tumors. Methods: Genomic DNA and total RNA were extracted from 45 and 32 neuroblastomas obtained from patients who had been diagnosed by clinical symptoms and from those detected by mass-screening, respectively, including tumors that subsequently spontaneously regressed or matured. Human whole genome microarrays (CodeLink ™  Human Whole Genome Bioarray) and single-nucleotide polymorphic allele arrays (Affimetrix ™  GeneChip Human mapping Array) were used to determine gene expression profiles, and whole genome aberrations, respectively. Results: Genome-wide genetic analysis using SNP arrays showed four major patterns consisting of whole chromosome gain/loss (W), partial chromosome gain/loss (P),  MYCN  gene amplification (M) and no large aberration (N). Twenty-seven (84%) MS detected tumors showed W or N pattern. DNA ploidy revealed that triploid tumors showed W pattern. The expression profiles of MS detected W and N tumors showed depressed expression of approximately 3000 genes and overexpression of 65 genes. These 65 genes contained apoptosis-related genes and cell spindle genes. On the other hand, most unfavorable tumors showed P or M patterns and showed 399 overexpressing genes, including  MYCN , mitochondria ribosomal proteins, transcription factors, and cell cycle regulatory proteins. Interestingly, many of these genes located at 1, 2, 3, 11, 14, or 17 chromosomes which were frequently altered in neuroblastoma. Only five MS detected tumors showed similar pattern with these unfavorable tumors. Conclusions: Combining genome-wide genetic analysis and expression profiling identified candidate genes leading into the spontaneous regression and maturation of neuroblastoma. In such tumors, repression of differentiating genes may have contributed to form favorable tumors which were mainly detected by 6-month old MS system. On the other hand, unfavorable tumors showed much more overexpressing genes with genetic aberrations.These data point toward key genes as candidates of risk assessment marker as well as therapeutic targets in neuroblastoma.
The R1306W Type 2B Natural Mutation of Von Willebrand Factor Dramatically Enhances the Multimer Sensitivity to Shear Stress
Authors: Raimondo De Cristofaro, Giovanni Luca Scaglione, Stefano Lancellotti, Maria Teresa Pagliari, Massimiliano Papi, Marco De Spirito, Alessandro Maiorana, Luciano Baronciani, Alessandro Arcovito, Enrico Di Stasio, Flora Peyvandi
Journal: Blood (2012)
Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity
Authors: Satomi Shimura, Koichi Watashi, Kento Fukano, Michael Peel, Ann Sluder, Fumihiro Kawai, Masashi Iwamoto, Senko Tsukuda, Junko S. Takeuchi, Takeshi Miyake, Masaya Sugiyama, Yuki Ogasawara, Sam-Yong Park, Yasuhito Tanaka, Hiroyuki Kusuhara, Masashi Mizokami, Camille Sureau, Takaji Wakita
Journal: Journal of Hepatology (2016)

The sodium taurocholate co-transporting polypeptide (NTCP) is the main target of most hepatitis B virus (HBV) specific entry inhibitors. Unfortunately, these agents also block NTCP transport of bile acids into hepatocytes, and thus have the potential to cause adverse effects. We aimed to identify small molecules that inhibit HBV entry while maintaining NTCP transporter function.
PD-L1 on Antigen-Presenting Cells Facilitate the Induction of Antigen-Specific Cytotoxic T Lymphocytes
Authors: Tatsunori Goto, Tetsuya Nishida, Erina Takagi, Kotaro Miyao, Daisuke Koyama, Reona Sakemura, Ryo Hanajiri, Keisuke Watanabe, Nobuhiko Imahashi, Seitaro Terakura, Makoto Murata, Hitoshi Kiyoi
Journal: Blood (2015)
Antibacterial Prophylaxis Reduces the Incidence of Neutropenic Fever and the Rate of Infections in Patients with Multiple Myeloma Who Undergo An Autologous Stem Cell Transplantation.
Authors: Evangelos Eleutherakis-Papaiakovou, Evangelos Kostis, Dimitrios Christoulas, Magdalini Migkou, Maria Gavriatopoulou, Maria Roussou, Despina Mparmparoussi, Charis Matsouka, Efstathios Manios, Eleni Efstathiou, Efstathios Kastritis, Evangelos Terpos, Meletios A. Dimopoulos, Christos Papadimitriou
Journal: Blood (2009)
High-specificity bioinformatics framework for epigenomic profiling of discordant twins reveals specific and shared markers for ACPA and ACPA-positive rheumatoid arthritis
Authors: David Gomez-Cabrero, Malin Almgren, Louise K. Sjöholm, Aase H. Hensvold, Mikael V. Ringh, Rakel Tryggvadottir, Juha Kere, Annika Scheynius, Nathalie Acevedo, Lovisa Reinius, Margaret A. Taub, Carolina Montano, Martin J. Aryee, Jason I. Feinberg, Andrew P. Feinberg, Jesper Tegnér, Lars Klareskog, Anca I. Catrina, Tomas J. Ekström
Journal: Genome Medicine (2016)

Twin studies are powerful models to elucidate epigenetic modifications resulting from gene–environment interactions. Yet, commonly a limited number of clinical twin samples are available, leading to an underpowered situation afflicted with false positives and hampered by low sensitivity. We investigated genome-wide DNA methylation data from two small sets of monozygotic twins representing different phases during the progression of rheumatoid arthritis (RA) to find novel genes for further research. We implemented a robust statistical methodology aimed at investigating a small number of samples to identify differential methylation utilizing the comprehensive CHARM platform with whole blood cell DNA from two sets of twin pairs discordant either for ACPA (antibodies to citrullinated protein antigens)-positive RA versus ACPA-negative healthy or for ACPA-positive healthy (a pre-RA stage) versus ACPA-negative healthy. To deconvolute cell type-dependent differential methylation, we assayed the methylation patterns of sorted cells and used computational algorithms to resolve the relative contributions of different cell types and used them as covariates. To identify methylation biomarkers, five healthy twin pairs discordant for ACPAs were profiled, revealing a single differentially methylated region (DMR). Seven twin pairs discordant for ACPA-positive RA revealed six significant DMRs. After deconvolution of cell type proportions, profiling of the healthy ACPA discordant twin-set revealed 17 genome-wide significant DMRs. When methylation profiles of ACPA-positive RA twin pairs were adjusted for cell type, the analysis disclosed one significant DMR, associated with the EXOSC1 gene. Additionally, the results from our methodology suggest a temporal connection of the protocadherine beta-14 gene to ACPA-positivity with clinical RA. Our biostatistical methodology, optimized for a low-sample twin design, revealed non-genetically linked genes associated with two distinct phases of RA. Functional evidence is still lacking but the results reinforce further study of epigenetic modifications influencing the progression of RA. Our study design and methodology may prove generally useful in twin studies.
The t(9;11) Confers Good Prognosis in AML Patients Treated with Stem Cell Transplantation As Compared to Non-t(9;11) and Other Adverse-Risk Abnormalities
Authors: Claudia Ulrike Walter, Fahed Almhareb, Naeem A. Chaudhri, Abu Jafar Saleh, Wahiba Chebbo, Ghada El Gohary, Hazzaa Al Zahrani, Said Mohamed, Walid Rasheed, Fahad Alsharif, Mahmoud Aljurf, Maher Albitar
Journal: Blood (2011)